Ozanimod (RPC-1063) is an investigational immunomodulatory drug currently in phase III clinical trials for the therapy of relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation. Shortly after , Inc. developed ozanimod, they were acquired by Celgene for $7.2 billion.

Property Value
dbo:abstract
  • Ozanimod (RPC-1063) is an investigational immunomodulatory drug currently in phase III clinical trials for the therapy of relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation. Shortly after , Inc. developed ozanimod, they were acquired by Celgene for $7.2 billion. (en)
dbo:casNumber
  • 1306760-87-1
dbo:drugbank
  • DB12612
dbo:fdaUniiCode
  • Z80293URPV
dbo:kegg
  • D10968
dbo:pubchem
  • 52938427
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-06 04:45:20Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 48035434 (xsd:integer)
dbo:wikiPageLength
  • 12299 (xsd:integer)
dbo:wikiPageModified
  • 2019-06-06 04:24:15Z (xsd:date)
dbo:wikiPageOutDegree
  • 20 (xsd:integer)
dbo:wikiPageRevisionID
  • 900508162 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Ozanimod (RPC-1063) is an investigational immunomodulatory drug currently in phase III clinical trials for the therapy of relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation. Shortly after , Inc. developed ozanimod, they were acquired by Celgene for $7.2 billion. (en)
rdfs:label
  • Ozanimod (en)
foaf:depiction
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of